Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Liabilities and Shareholders Equity (2019 - 2026)

C4 Therapeutics has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $328.9 million for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 2.92% year-over-year to $328.9 million; the TTM value through Mar 2026 reached $1.2 billion, down 12.36%, while the annual FY2025 figure was $359.1 million, 2.71% up from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $328.9 million at C4 Therapeutics, down from $359.1 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $515.5 million in Q1 2022 and troughed at $265.5 million in Q3 2025.
  • A 5-year average of $379.7 million and a median of $376.1 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 37.83% in 2022 and later dropped 29.4% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $430.8 million in 2022, then fell by 12.62% to $376.5 million in 2023, then fell by 7.13% to $349.6 million in 2024, then grew by 2.71% to $359.1 million in 2025, then decreased by 8.41% to $328.9 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for CCCC at $328.9 million in Q1 2026, $359.1 million in Q4 2025, and $265.5 million in Q3 2025.